标题：肿瘤坏死因子拮抗剂治疗风湿病的临床疗效分析

      作者：丁 菱 1，何善智 1，钟伟秋 2
    (中山市人民医院风湿免疫科 1、内科门诊 2，广东 中山 528403)

      卷次： 2012年23卷8期

      【摘要】 目的 探讨肿瘤坏死因子拮抗剂(依那西普)对风湿病的临床疗效。方法 将我院收治的类风湿性
关节炎患者52例随机分为实验组(27例)以及对照组(25例)，实验组采用依那西普进行治疗，对照组采用硫酸羟氯
喹片治疗，对患者进行为期6个月的随访。结果 实验组患者临床有效率为92.59%，显著高于对照组的76.00%；
实验组患者在治疗后关节疼痛数、关节压痛积分、晨僵、20 m步行时间、关节肿胀积分等临床指标比较中均优于
对照组(P＜0.05)；实验组患者在治疗后其风湿因子、C反应蛋白、血沉治疗后指标较对照组差异均有统计学意义
(P＜0.05)。结论 对风湿病患者采用肿瘤坏死因子拮抗剂进行治疗，可有效改善患者预后，提高患者治疗后生
活质量。

      【关键词】 依那西普；风湿病；疗效

      【中图分类号】 R593.2 【文献标识码】 A 【文章编号】 1003—6350(2012)08—027—03<

br>Clinical effect of tumor necrosis factor antagonists in the treatment of rheumatology.
DING Ling 1, HE Shan-zhi 1,
ZHONG Wei-qiu 2. Department of Rheumatology & Immunology 1, Internal Medicine Clinic 2, People's Hospital of
Zhongshan City, Zhongshan 528403, Guangdong, CHINA

【Abstract】 Objective To investigate the clinical effect of tumor necrosis factor antagonist (etanercept) in the
treatment of rheumatology. Methods Fifty-two patients with rheumatoid arthritis were randomly divided into the
study group and the control group. Patients in the study group were treated with etanercept, while those in the control
group were treated with conventional treatment using hydroxychloroquine sulfate. All the patients were followed up
for 6 months. Results The effective rate of the study group was 92.59%, significantly higher than 76.00% in the con-
trol group. The clinical indicators, including the number of joint pain, points of joint tenderness, morning stiffness,
time to walk each 20 m points of joint swelling, were better than those in the control group. The improvement of rheu-
matoid factor, C-reactive protein, erythrocyte sedimentation rate after treatment in the study group was better than
those in the control group (P<0.05). Conclusion Tumor necrosis factor antagonist treatment can effectively improve
the prognosis of rheumatic patients and promote their quality of life after treatment.

      【Key words】 Etanercept; Rheumatism; Effect